[177lu]lu-sn201

Recurrent Solid Tumor

Spago Nanomedical ABradiopharmaceuticalPhase 1/2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 95/ 100

Competitive context

1411 Active assets in the Recurrent Solid Tumor cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

[177lu]lu-sn201 is also rated in:

Unresectable Solid TumorDormant

CC

Indicative ·

47 / 100

Locally Advanced Solid TumorDormant

CC

Indicative ·

45 / 100

metastatic malignant neoplasmDormant

CC

Indicative ·

43 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.